Glenmark Pharma India sales jump 704.2% to ₹1,327.4 crore
In short
Glenmark Pharma reported India business revenue of ₹1,327.4 crore, up 704.2% from ₹165.1 crore a year earlier.
On a like-for-like basis, its India formulation business grew about 14% in Q2FY27. That is why the stock may move when markets open.
What the reporting says
Glenmark Pharma reported India business revenue of ₹1,327.4 crore, up 704.2% from ₹165.1 crore in the year-ago quarter. On a like-for-like basis, the company’s India formulation business grew about 14% in Q2FY27. The update is set to drive share reaction as investors compare the headline surge with the underlying business growth.
Why it matters
Glenmark Pharma reported India business revenue of ₹1,327.4 crore, sharply higher than ₹165.1 crore in the year-ago quarter. The company’s India formulation business also grew about 14% on a like-for-like basis in Q2FY27. The headline jump and underlying growth are likely to shape the market’s reaction to the stock.